Dynamic Changes in Circulating Tumour Cells Protein Expression

Summary

This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4).

Eligibility

Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 to 2 (scores range from 0 to 5, with higher numbers reflecting greater disability) ,
* medically able to receive chemotherapy.

Exclusion Criteria:

* evidence of infective disease before enrollment ,
* a history of another primary cancer within the previous 3 years,
* the presence of synchronous primary colorectal cancer.

Conditions2

Browse More Trials